(Q35184579)

7 August 2017

title

Antiretroviral-associated liver injury (English)

1 reference

7 August 2017

main subject

anti-retroviral agent

0 references

2

Mark S Sulkowski

1 reference

7 August 2017

Anthony O Ogedegbe

1

1 reference

7 August 2017

publication date

1 May 2003

1 reference

7 August 2017

published in

Clinics in liver disease

1 reference

7 August 2017

volume

7

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

475-499

1 reference

Antiretroviral drug toxicity -- a challenge for the hepatologist?

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Long-term exposure to lifelong therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Alcohol and Other Substance Use in STD Clinic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The relationship between risk networks' patterns of crack cocaine and alcohol consumption and HIV-related sexual behaviors among adult injection drug users: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Clinical toxicity of antiretroviral nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The liver in the acquired immunodeficiency syndrome: a clinical and histologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Pathologic features of the liver in acquired immune deficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatic Histopathology in the Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

1 reference

7 January 2021

Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A Severe, Unusual Reaction to Trimethoprim-Sulfamethoxazole in Patients Infected with Human Immunodeficiency Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Zidovudine-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatomegaly with severe steatosis in HIV-seropositive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe hepatitis in three AIDS patients treated with indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Rates and risk factors for adverse events associated with didanosine in the expanded access program

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Biologic effects and safety of stavudine: overview of phase I and II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Lactic acidosis associated with stavudine administration: a report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Liver failure associated with mitochondrial DNA depletion

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial toxicity and HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatic Morphological alterations induced by zidovudine (ZDV) in an experimental model

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial myopathy caused by long-term zidovudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Management of hyperlactatemia: no need for routine lactate measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Kaletra (lopinavir/ritonavir).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Role of therapeutic drug monitoring for protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Critical issues in therapeutic drug monitoring of antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

1 reference

7 January 2021

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe hepatic failure related to nevirapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Efavirenz-induced photoallergic dermatitis in HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hypersensitivity syndrome associated with efavirenz therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Efavirenz-induced acute eosinophilic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

The tolerability of efavirenz after nevirapine-related adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

HCV chronic hepatitis in patients with HIV: clinical management issues

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hyperlactatemia syndromes in people with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial toxic effects and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial toxic effects and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Riboflavine and severe lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Clinical features and natural history of nonalcoholic steatosis syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Cytokines in alcoholic and nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Etiopathogenesis of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

Excess Mortality From Liver Disease and Other Non–AIDS-Related Diseases Among HIV-Infected Individuals in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900023-0

7 January 2021

10.1016/S1089-3261(03)00023-0

Identifiers

DOI

1 reference

7 August 2017

1 reference